An RCT of cannabinoid replacement therapy (Sativex®) for the management of treatment-resistant cannabis dependent patients [ 2015 - 2017 ]

Research Grant

Researchers: Prof Nicholas Lintzeris (Principal investigator) ,  A/Pr David Allsop ,  A/Pr Raimondo Bruno ,  Dr Marian Shanahan ,  Prof Adrian Dunlop
View all 7 related researchers

Brief description This project is the first-ever outpatient RCT to test if the pharmaceutical cannabinoid Sativex can safely and cost-effectively deliver better treatment outcomes for patients seeking treatment for chronic cannabis dependence. Sativex is a mouth spray with equal parts THC and cannabidiol, and appears to have a safer pharmacological profile than illicit cannabis or synthetic THC alone. Thus Sativex may lead to lower rates of psychiatric adverse events and increased cannabis abstinence rates.

Funding Amount $AUD 788,133.38

Funding Scheme Project Grants

Notes Standard Project Grant